Research Reports

Sai Life Sciences Q1 FY27: consolidated PAT up 21% YoY to ₹73 Cr as margins expand

crdmo · pharma cdmo · margin expansion

Lupin Q1 FY27: PBT +43% YoY beats Street; PAT growth muted by tax normalization

pharmaceuticals · acquisition integration · tax normalization

Vijaya Diagnostic Q1FY27: PAT +37.6% YoY on margin expansion, revenue up 22.8%

diagnostics · margin expansion · pat growth

Jenburkt Q1 FY27: PAT falls 24% YoY as staff costs surge, margins compress

pharmaceuticals · margin compression · employee costs

HCG Q1 FY27: consolidated PAT up 175% YoY to ₹16.5 Cr as NPM more than doubles to 2.4%

oncology hospitals · margin expansion · npm improvement

Hikal Q1FY27: consolidated loss narrows to ₹7.4 Cr YoY as margins expand, revenue up 6%

specialty chemicals · pharma segment · crop protection

Albert David Q1 FY27: standalone PAT surges 303% YoY to ₹32 Cr as margins expand sharply

pharmaceuticals · margin expansion · tax credit

P&G Health Q1: revenue +7% YoY but core PAT down ~3% adjusted for one-off land-sale gain

pharmaceuticals · one-off gain · asset sale

Zim Labs' consolidated loss widens to ₹4.02 Cr in Q1 FY27 as margins compress

pharmaceuticals · generics · eu gmp

Emcure Q1FY27: consolidated PAT up 36% YoY to ₹292 Cr, margins expand, revenue +23%

pharma exports · margin expansion · international revenue growth

Consolidated loss widens 148% YoY to ₹127.6 Cr as R&D spend surges on Phase 3 trials

clinical stage biopharma · phase 3 trial · r&d expense surge

Aurobindo Q1 FY27: consolidated PAT +25% YoY to ₹1,032 Cr as margins near 21% target

pharma · consolidated results · margin expansion

Aster DM Quality Care Q1: PAT crashes on ₹114cr merger cost; EBITDA still +27.5% YoY

hospital chain · healthcare · merger integration

Biocon Q1FY27: Consolidated PAT Up 53% YoY to ₹137 Cr as BBL Becomes Wholly Owned

biosimilars growth · margin expansion · crdmo headwinds

Neuland Q1 FY27: consolidated PAT jumps 6x YoY to ₹147.7 Cr, margins cool from Q4 peak

api cdmo · sterile apis · margin normalization

Shilpa Medicare Q1 FY27: PAT ₹101 Cr, +115% YoY but adjusted growth ~61% ex tax boost

deferred tax reversal · margin expansion · biologics cdmo

Fredun Pharma Q1FY27: consolidated PAT +94% YoY to ₹13.1 Cr, revenue nearly doubles, margins expand

pharmaceuticals · consolidated results · margin expansion

Metropolis Q1FY27: consol PAT +25.7% YoY to ₹56.9 Cr, margin gain meets FY27 guide

diagnostics · pathology services · margin expansion

Novartis India: When Global Pharma Steps Back

promoter exit · private equity acquisition · ChrysCapital

Morepen Labs consolidated PAT surges 425% YoY to ₹56.4 Cr on record revenue, margins triple

pharma · cdmo · margin expansion

Alembic Q1FY27 revenue up 26% YoY beats guidance; US ramp drags consol PAT growth to 12%

us generics ramp · margin compression · revenue beat

Dr Agarwal's Q1 PAT up 44.6% YoY to ₹55 Cr as margins expand, revenue grows 26%

eye care · hospital chain · margin expansion

Novartis Steps Back: A ₹1,376 Crore Strategic Exit from India

Acquisition · Private Equity · Pharma

Credibility quarter: Can new management establish execution amid ambitious FY27 growth?

New CEO's First Print: Can Umang Vohra Stabilize API Plus While Scaling Specialty?

US specialty ramp under way—watch ANDA momentum & margin durability

specialty generics · ANDA approvals · oncology pivot

Strong growth, integration questions — Q1 sets FY27 tone amid Agarwal's Eye Hospital merger

margin sustainability · merger integration · facility expansion

Post-Q4 euphoria: Can Gland sustain momentum with Sugammadex on the board?

generic pharma · USFDA approval · Sugammadex launch

Hospital margin expansion on track; watch diagnostics for pivot to double-digit growth

hospital margins · diagnostics growth · capacity expansion

KIMS Q1FY27: consolidated PAT down 56% YoY on expansion costs, revenue up 35%

hospitals · healthcare · margin compression